Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr;120(4):1108-1119.
doi: 10.1002/bit.28313. Epub 2023 Jan 3.

αCT1 peptide sensitizes glioma cells to temozolomide in a glioblastoma organoid platform

Jingru Che  1 , Thomas J DePalma  1   2 , Hemamylammal Sivakumar  1 , Louisa S Mezache  1   3 , Miranda M Tallman  4   5 , Monica Venere  2   5 , Katelyn Swindle-Reilly  1   6   7 , Rengasayee Veeraraghavan  1   3 , Aleksander Skardal  1   2   8
Affiliations

αCT1 peptide sensitizes glioma cells to temozolomide in a glioblastoma organoid platform

Jingru Che et al. Biotechnol Bioeng. 2023 Apr.

Abstract

Glioblastoma (GBM) is the most common form of brain cancer. Even with aggressive treatment, tumor recurrence is almost universal and patient prognosis is poor because many GBM cell subpopulations, especially the mesenchymal and glioma stem cell populations, are resistant to temozolomide (TMZ), the most commonly used chemotherapeutic in GBM. For this reason, there is an urgent need for the development of new therapies that can more effectively treat GBM. Several recent studies have indicated that high expression of connexin 43 (Cx43) in GBM is associated with poor patient outcomes. It has been hypothesized that inhibition of the Cx43 hemichannels could prevent TMZ efflux and sensitize otherwise resistance cells to the treatment. In this study, we use a three-dimensional organoid model of GBM to demonstrate that combinatorial treatment with TMZ and αCT1, a Cx43 mimetic peptide, significantly improves treatment efficacy in certain populations of GBM. Confocal imaging was used to visualize changes in Cx43 expression in response to combinatorial treatment. These results indicate that Cx43 inhibition should be pursued further as an improved treatment for GBM.

Keywords: Connexin 43; glioblastoma; organoids; temozolomide.

PubMed Disclaimer

References

REFERENCES

    1. Ahmed, A. U., Auffinger, B., & Lesniak, M. S. (2013). Understanding glioma stem cells: Rationale, clinical relevance and therapeutic strategies. Expert Review of Neurotherapeutics, 13(5), 545-555.
    1. Allen, M., Bjerke, M., Edlund, H., Nelander, S., & Westermark, B. (2016). Origin of the U87MG glioma cell line: Good news and bad news. Science Translational Medicine, 8(354), 354re353.
    1. Auffinger, B., Spencer, D., Pytel, P., Ahmed, A. U., & Lesniak, M. S. (2015). The role of glioma stem cells in chemotherapy resistance and glioblastoma multiforme recurrence. Expert Review of Neurotherapeutics, 15(7), 741-752.
    1. Binabaj, M. M., Bahrami, A., ShahidSales, S., Joodi, M., Joudi Mashhad, M., Hassanian, S. M., Anvari, K., & Avan, A. (2018). The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials. Journal of Cellular Physiology, 233(1), 378-386.
    1. Costa, E. C., Moreira, A. F., de Melo-Diogo, D., Gaspar, V. M., Carvalho, M. P., & Correia, I. J. (2016). 3D tumor spheroids: An overview on the tools and techniques used for their analysis. Biotechnology Advances, 34(8), 1427-1441.

Publication types

LinkOut - more resources